Insider Selling: ADMA Biologics (NASDAQ:ADMA) Director Sells $139,200.00 in Stock

ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) Director Lawrence Guiheen sold 10,000 shares of ADMA Biologics stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $13.92, for a total transaction of $139,200.00. Following the sale, the director owned 63,599 shares in the company, valued at approximately $885,298.08. This represents a 13.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ADMA Biologics Price Performance

ADMA stock traded down $0.22 during trading on Monday, hitting $13.46. The company had a trading volume of 3,050,514 shares, compared to its average volume of 4,078,892. The firm has a market capitalization of $2.99 billion, a price-to-earnings ratio of 17.19 and a beta of 0.65. The business has a 50 day moving average of $10.65 and a 200 day moving average of $10.77. ADMA Biologics Inc has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The company has a current ratio of 6.04, a quick ratio of 3.25 and a debt-to-equity ratio of 0.45.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. The firm had revenue of $141.10 million during the quarter, compared to analyst estimates of $138.11 million. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.56%. ADMA Biologics’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.15 EPS. As a group, research analysts predict that ADMA Biologics Inc will post 0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their price target on shares of ADMA Biologics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, November 5th. Mizuho set a $18.00 price objective on shares of ADMA Biologics in a research note on Thursday, November 5th. Zacks Research upgraded shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, ADMA Biologics has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.

Read Our Latest Stock Report on ADMA

Institutional Trading of ADMA Biologics

Institutional investors have recently modified their holdings of the company. Entropy Technologies LP raised its position in ADMA Biologics by 234.4% in the third quarter. Entropy Technologies LP now owns 75,592 shares of the biotechnology company’s stock worth $758,000 after acquiring an additional 52,990 shares in the last quarter. Jump Financial LLC lifted its holdings in ADMA Biologics by 156.1% in the 3rd quarter. Jump Financial LLC now owns 460,907 shares of the biotechnology company’s stock valued at $4,623,000 after acquiring an additional 280,907 shares during the last quarter. Caxton Associates LLP boosted its position in shares of ADMA Biologics by 5.8% during the 3rd quarter. Caxton Associates LLP now owns 42,256 shares of the biotechnology company’s stock valued at $424,000 after purchasing an additional 2,328 shares in the last quarter. Nantahala Capital Management LLC boosted its position in shares of ADMA Biologics by 9.8% during the 3rd quarter. Nantahala Capital Management LLC now owns 2,590,475 shares of the biotechnology company’s stock valued at $25,982,000 after purchasing an additional 230,482 shares in the last quarter. Finally, Bleakley Financial Group LLC boosted its position in shares of ADMA Biologics by 53.1% during the 3rd quarter. Bleakley Financial Group LLC now owns 50,388 shares of the biotechnology company’s stock valued at $505,000 after purchasing an additional 17,471 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

(Get Free Report)

ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.

Recommended Stories

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.